278 related articles for article (PubMed ID: 32560043)
1. Computational Drug Repositioning for Chagas Disease Using Protein-Ligand Interaction Profiling.
Juárez-Saldivar A; Schroeder M; Salentin S; Haupt VJ; Saavedra E; Vázquez C; Reyes-Espinosa F; Herrera-Mayorga V; Villalobos-Rocha JC; García-Pérez CA; Campillo NE; Rivera G
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560043
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase.
Schormann N; Velu SE; Murugesan S; Senkovich O; Walker K; Chenna BC; Shinkre B; Desai A; Chattopadhyay D
Bioorg Med Chem; 2010 Jun; 18(11):4056-66. PubMed ID: 20452776
[TBL] [Abstract][Full Text] [Related]
3. Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate.
Senkovich O; Schormann N; Chattopadhyay D
Acta Crystallogr D Biol Crystallogr; 2009 Jul; 65(Pt 7):704-16. PubMed ID: 19564691
[TBL] [Abstract][Full Text] [Related]
4. Repositioned Drugs for Chagas Disease Unveiled via Structure-Based Drug Repositioning.
Adasme MF; Bolz SN; Adelmann L; Salentin S; Haupt VJ; Moreno-Rodríguez A; Nogueda-Torres B; Castillo-Campos V; Yepez-Mulia L; De Fuentes-Vicente JA; Rivera G; Schroeder M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233837
[TBL] [Abstract][Full Text] [Related]
5. Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.
Senkovich O; Bhatia V; Garg N; Chattopadhyay D
Antimicrob Agents Chemother; 2005 Aug; 49(8):3234-8. PubMed ID: 16048931
[TBL] [Abstract][Full Text] [Related]
6. Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies.
Palos I; Lara-Ramirez EE; Lopez-Cedillo JC; Garcia-Perez C; Kashif M; Bocanegra-Garcia V; Nogueda-Torres B; Rivera G
Molecules; 2017 Jun; 22(6):. PubMed ID: 28629155
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
Monteiro ME; Lechuga G; Lara LS; Souto BA; Viganó MG; Bourguignon SC; Calvet CM; Oliveira FOR; Alves CR; Souza-Silva F; Santos MS; Pereira MCS
Eur J Med Chem; 2019 Nov; 182():111610. PubMed ID: 31434040
[TBL] [Abstract][Full Text] [Related]
8. Novel drug design for Chagas disease via targeting Trypanosoma cruzi tubulin: Homology modeling and binding pocket prediction on Trypanosoma cruzi tubulin polymerization inhibition by naphthoquinone derivatives.
Ogindo CO; Khraiwesh MH; George M; Brandy Y; Brandy N; Gugssa A; Ashraf M; Abbas M; Southerland WM; Lee CM; Bakare O; Fang Y
Bioorg Med Chem; 2016 Aug; 24(16):3849-55. PubMed ID: 27345756
[TBL] [Abstract][Full Text] [Related]
9. Crystallization and preliminary crystallographic studies of dihydrofolate reductase-thymidylate synthase from Trypanosoma cruzi, the Chagas disease pathogen.
Chitnumsub P; Yuvaniyama J; Chahomchuen T; Vilaivan T; Yuthavong Y
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2009 Nov; 65(Pt 11):1175-8. PubMed ID: 19923744
[TBL] [Abstract][Full Text] [Related]
10. Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds Inhibiting Putrescine Uptake.
Alberca LN; Sbaraglini ML; Morales JF; Dietrich R; Ruiz MD; Pino Martínez AM; Miranda CG; Fraccaroli L; Alba Soto CD; Carrillo C; Palestro PH; Talevi A
Front Cell Infect Microbiol; 2018; 8():173. PubMed ID: 29888213
[TBL] [Abstract][Full Text] [Related]
11. Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease.
Haupt VJ; Aguilar Uvalle JE; Salentin S; Daminelli S; Leonhardt F; Konc J; Schroeder M
Curr Pharm Des; 2016; 22(21):3124-34. PubMed ID: 26873186
[TBL] [Abstract][Full Text] [Related]
12. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
de Oliveira Filho GB; Cardoso MVO; Espíndola JWP; Oliveira E Silva DA; Ferreira RS; Coelho PL; Anjos PSD; Santos ES; Meira CS; Moreira DRM; Soares MBP; Leite ACL
Eur J Med Chem; 2017 Dec; 141():346-361. PubMed ID: 29031078
[TBL] [Abstract][Full Text] [Related]
13. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
14. Repositioning FDA-Approved Drug Against Chagas Disease and Cutaneous Leishmaniosis by Structure-Based Virtual Screening.
Juarez-Saldivar A; Gómez-Escobedo R; Corral-Ruiz G; Chacón-Vargas KF; Horta-Montaño V; Sanchez-Torres L; Vazquez-Jimenez LK; Nogueda-Torres B; Rivera G
Arch Med Res; 2024 Feb; 55(2):102958. PubMed ID: 38290200
[TBL] [Abstract][Full Text] [Related]
15. A structure-based approach towards the identification of novel antichagasic compounds:
Llanos MA; Sbaraglini ML; Villalba ML; Ruiz MD; Carrillo C; Alba Soto C; Talevi A; Angeli A; Parkkila S; Supuran CT; Gavernet L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):21-30. PubMed ID: 31619095
[No Abstract] [Full Text] [Related]
16. Crystal violet structural analogues identified by in silico drug repositioning present anti-Trypanosoma cruzi activity through inhibition of proline transporter TcAAAP069.
Sayé M; Gauna L; Valera-Vera E; Reigada C; Miranda MR; Pereira CA
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007481. PubMed ID: 31961864
[TBL] [Abstract][Full Text] [Related]
17. Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
Keenan M; Abbott MJ; Alexander PW; Armstrong T; Best WM; Berven B; Botero A; Chaplin JH; Charman SA; Chatelain E; von Geldern TW; Kerfoot M; Khong A; Nguyen T; McManus JD; Morizzi J; Ryan E; Scandale I; Thompson RA; Wang SZ; White KL
J Med Chem; 2012 May; 55(9):4189-204. PubMed ID: 22536986
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, molecular docking and biological evaluation of novel phthaloyl derivatives of 3-amino-3-aryl propionic acids as inhibitors of Trypanosoma cruzi trans-sialidase.
Kashif M; Chacón-Vargas KF; López-Cedillo JC; Nogueda-Torres B; Paz-González AD; Ramírez-Moreno E; Agusti R; Uhrig ML; Reyes-Arellano A; Peralta-Cruz J; Ashfaq M; Rivera G
Eur J Med Chem; 2018 Aug; 156():252-268. PubMed ID: 30006170
[TBL] [Abstract][Full Text] [Related]
19. Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase.
Zuccotto F; Zvelebil M; Brun R; Chowdhury SF; Di Lucrezia R; Leal I; Maes L; Ruiz-Perez LM; Gonzalez Pacanowska D; Gilbert IH
Eur J Med Chem; 2001 May; 36(5):395-405. PubMed ID: 11451529
[TBL] [Abstract][Full Text] [Related]
20. High-throughput drug repositioning for the discovery of new treatments for Chagas disease.
Bellera CL; Sbaraglini ML; Balcazar DE; Fraccaroli L; Vanrell MC; Casassa AF; Labriola CA; Romano PS; Carrillo C; Talevi A
Mini Rev Med Chem; 2015; 15(3):182-93. PubMed ID: 25769967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
